Phase 2 open-label RCT in 242 nondiabetic women with localised HER2-positive or triple-negative breast cancer: adding metformin to neoadjuvant chemotherapy did not significantly improve pCR (43.7% vs 41.7%; 227 analysed). Diarrhoea was more frequent.
RCTn = 242
Mouna et al. Metformin with neoadjuvant chemotherapy in localized triple-negative and Her2neu-positive breast cancer: A prospective phase 2 open-label randomized controlled trial (McBETH)